NCIt definition : A bispecific antibody comprised of a humanized anti-CD3 OKT3 (huOKT3) single chain
variable fragment (scFv), linked to the carboxyl end of a humanized anti-GD2 3F8 (hu3F8)
immunoglobulin G1 (IgG1) light chain, with potential antineoplastic activity. Upon
intravenous administration, nivatrotamab binds to CD3 on T-cells and disialoganglioside
GD2 expressed on certain tumor cells, thereby cross-linking T-cells with GD2-expressing
tumor cells. This promotes a selective cytotoxic T-lymphocyte (CTL) response against
GD2-expressing cells. The Fc region of the anti-GD2 hu3F8/anti-CD3 huOKT3 bispecific
antibody has two amino acid substitutions, N297A and K322A, which may prevent cytokine
release syndrome and other unwanted side effects including complement-mediated pain.
GD2, a disialoganglioside and tumor-associated antigen (TAA), is overexpressed in
a variety of tumor cell types. CD3 is part of the functional T-cell receptor (TCR)
complex, which is necessary for antigen recognition by T-cells and is required for
signal transduction.;
UNII : 8RV18E4A94;
CAS number : 2278244-14-5; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2278244-14-5
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Semantic type(s)